caa a22 4500 46573538X CHVBK 20180323111753.0 cr unu---uuuuu 170327e19901001xx s 000 0 eng 10.1007/BF02427837 doi (NATIONALLICENCE)springer-10.1007/BF02427837 Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors [Elektronische Daten] [Lynn Feun, Niramol Savaraj, Howard Landy, Howard Levin, Theodore Lampidis] A phase 11 trial of Homoharringtonine (HHT) was performed in 15 patients with recurrent or progressive malignant glioma. The drug was administered at a initial dose of 4 mg/m2/day by continuous 5 day intravenous infusion (3 mg/m2/day x 5 days for heavily pretreated patients). Courses were repeated every 3-4 weeks upon recovery from toxicity. No objective antitumor regressions occurred. Two patients had no change in their CT brain scans for 2-3 months and one patient had stable disease for 6 months. Toxicity was tolerable and included myelosuppression and occasionally mild hypotension. Chemosensitivity testing with HHT and several other chemotherapy drugs was performed in glioma cell lines, including cell lines derived from these patients. The results suggest that HHT is an inactive drug in malignant glioma using this dose schedule. Kluwer Academic Publishers, 1990 homoharringtonine nationallicence central nervous system nationallicence tumor nationallicence Feun Lynn Department of oncology, University of Miami, Miami, FL, USA aut Savaraj Niramol Department of oncology, University of Miami, Miami, FL, USA aut Landy Howard Neurosurgery, University of Miami, Miami, FL, USA aut Levin Howard Neurology, University of Miami, Miami, FL, USA aut Lampidis Theodore Department of oncology, University of Miami, Miami, FL, USA aut Journal of Neuro-Oncology Kluwer Academic Publishers 9/2(1990-10-01), 159-163 0167-594X 9:2<159 1990 9 11060 https://doi.org/10.1007/BF02427837 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02427837 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Feun Lynn Department of oncology, University of Miami, Miami, FL, USA aut NATIONALLICENCE 700 1- Savaraj Niramol Department of oncology, University of Miami, Miami, FL, USA aut NATIONALLICENCE 700 1- Landy Howard Neurosurgery, University of Miami, Miami, FL, USA aut NATIONALLICENCE 700 1- Levin Howard Neurology, University of Miami, Miami, FL, USA aut NATIONALLICENCE 700 1- Lampidis Theodore Department of oncology, University of Miami, Miami, FL, USA aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 9/2(1990-10-01), 159-163 0167-594X 9:2<159 1990 9 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer